Psychiatry

Following is a digest of pharmacogenomics journal articles pertaining to psychiatry. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.


Article Citation & LinkTypeMonthSNP•its Study Summary
Brown JT et al. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther. 2015 Dec 11 [Epub ahead of print].Pharmacokinetic2015-12
Bishop JR et al. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015;25:548-54.Cohort2015-11
van de Bilt MT et al. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment. Schizophr Res. 2015;168:587-8.
Case Control2015-10
Walden LM et al. Physicians' opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res. 2015;229:913-8.Observational2015-10
Fijal BA et al. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. J Clin Pharmacol. 2015;55:1167-74.Post hoc analysis2015-10
Winner JG et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;31:1633–43. Prospective Cohort2015-09
Tomaz PR et al. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. Eur J Clin Pharmacol. 2015;71:1067–73.Retrospective Cohort2015-09
Uckun Z et al. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. J Clin Pharm Ther. 2015;40:672-9Case Control2015-09
Zhan YY,et al. Effect of CYP2D6 variants on venlafaxine metabolism in vitro. Xenobiotica. 2015 Sep 25 [Epub ahead of print].PK/PD2015-09
Brown JT et al. Atomoxetine pharmacogenetics: associations with
pharmacokinetics, treatment response and tolerability.
Pharmacogenomics.
2015;16:1513-20.
Review2015-08
Probst-Schendzielorz K et al. Effect of cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. Expert Opin Drug Metab Toxicol. 2015;11:1219-32.Review2015-08
Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci. 2015;13:150-6Randomized Controlled Trial2015-08
Peters ME et al. Citalopram for the treatment of agitation in Alzheimer dementia: genetic influences. J Geriatr Psychiatry Neurol. 2015 Aug 23 [Epub ahead of print].Retrospective Cohort2015-08
Garmén AK et al. Extreme duration of diazepam-associated sedation in a patient with alcohol delirium and CYP2C19 polymorphisms. J Clin Psychopharmacol. 2015;35:475-7.Case Report2015-08
Haufroid V et al. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Clin Toxicol. 2015;53:501-10.Review2015-07
Caldirola D et al. Is there a role for pharmacogenetics in the treatment of panic disorder? Pharmacogenomics. 2015;16:771-4.Editorial2015-07
Vandenberghe F et al. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet. 2015 Jul 1 [Epub ahead of print].PK2015-07
Winner JG et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a one year prospective evaluation. Curr Med Res Opin. 2015 July 23 [Epub ahead of print].Cost-effectiveness analysis2015-07
Chen R et al. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. Eur J Clin Pharmacol. 2015;7:835-41.PK/PD2015-07
Devlin AM et al. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. Pharmacogenomics. 2015;16:981-6.Review2015-06
Brennan FX et al. Naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord. 2015;17(2).Prospective Cohort2015-04
Van der Weide K et al. The Influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015;35:228-36.PK/PD2015-04
Helton SG et al. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015;16:541–53.Review2015-04
Cabaleiro T et al. Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. Int Clin Psychopharmacol. 2015;30:82–8.PK/PD2015-03
Hodgson K et al. Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology (Berl). 2015 Mar 12 [Epub ahead of print].cross-sectional2015-03
Kato M et al. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Transl Psychiatry. 2015;5:e513.Retrospective analysis2015-02
Altar CA et al. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J. 2015 Feb 17 [Epub ahead of print].Retrospective analysis 2015-02
Smith T et al. Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report. Int J Mol Sci. 2015;16:4416-28.Case Report2015-02
Smith T et al. Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report. Int J Mol Sci. 2015;16:4416–28.Case Report2015-02
Hamilton SP. The promise of psychiatric pharmacogenomics. Biol Psychiatry. 2015;77:29–35.Review2015-01
Dubovsky SL. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression. Expert Opin Drug Metab Toxicol. 2015;1–11.Expert opinion2015-01
Gardner KR et al. The potential utility of pharmacogenetic testing in psychiatry. Psychiatry J. 2014;2014:730956.Review2014-12
Thompson C et al. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care. Psychiatry Res. 2014 Dec 4 [Epub ahead of print].Cross sectional survey2014-12
Gassó P et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 2014;14:457–62.Prospective Cohort2014-11
Levy F. Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder. Pharmgenomics Pers Med. 2014;7:349–56.Review2014-11
Zhu AZX et al. Gene Variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab Dispos. 2014;42:1971–7.PK/PD Study2014-11
Ceskova E. The need to improve current psychopharmacotherapy before developing new drugs. Expert Opin Pharmacother. 2014;15:1969–73.Editorial2014-11
Sicras-Mainar A et al. Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS ONE. 2014;9:e90453.Retrospective Cohort2014-11
Bowers K et al. Pharmacogenomic Medicine in Autism: Challenges and Opportunities. Paediatr Drugs. 2014 Nov 25 [Epub ahead of print].Review2014-11
Howland RH. Pharmacogenetic testing in psychiatry: not (quite) ready for primetime. J Psychosoc Nurs Ment Health Serv. 2014;52:13–6.Perspective2014-11
Stevenson JM et al. Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction. Pharmacogenomics. 2014;15:1791–1806.Review2014-11
Chang FC et al. Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. Pharmgenomics Pers Med. 2014;7:317–28.Review2014-10
Suzuki T et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and Its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit. 2014;36:651–5.PK/PD Study2014-10
Stingl J et al. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med. 2014 Oct 8 [Epub ahead of print].Review2014-10
Nussbaum LA et al. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Rom J Morphol Embryol. 2014;55:877–84.Prospective Cohort2014-10
Tybura P et al. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Psychiatry Res. 2014;219:261–7.Randomized trial2014-10
Garfield LD et al. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Am J Geriatr Psychiatry. 2014;22:971–9.Randomized Clinical Trial2014-10
Youngster I et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol. 2014;56:990–4.Retrospective Cohort Study2014-10
Chang M et al. Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis. Clin Pharmacokinet. 2014;53:801-11.Systematic review and meta-analysis2014-09Escitalopram, citalopram: Are higher doses needed in CYP2C19 ultrarapid metabolizers?
Zhu AZ et al. Gene Variants in CYP2C19 are Associated with Altered In Vivo Bupropion Pharmacokinetics but not Bupropion Assisted Smoking Cessation Outcomes. Drug Metab Dispos. 2014 Sep [Epub ahead of print].Pharmacokinetics and clinical study2014-09 
Spina E et al. Clinical applications of CYP genotyping in psychiatry. Journal of Neural Transmission. 2014; [Epub ahead of print].Review2014-09 
Fagerness J et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20:e146–56.Retrospective Cohort2014-09
Cabaleiro T et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol. 2014;29:459–69.PK2014-09
Bakken GV et al. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients. Ther Drug Monit. 2014 Sep [Epub ahead of print].Pharmacokinetic2014-09 
Kumar Y et al. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. J Psychopharmacol. 2014 Aug; [Epub ahead of print].Retrospective cohort2014-08 
Waade RB et al. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol. 2014;70:933–40.Retrospective cohort study

 
2014-08 
Fabbri C et al. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opin Drug Metab Toxicol. 2014;10:1093-118.Review2014-08 
Cabaleiro T et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, andsafety of risperidone in healthy volunteers. Hum Psychopharmacol. 2014 Jul 9; [Epub ahead of print].Pharmacokinetic, pharmacodynamic2014-07 
Tybura P et al. Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine. Psychiatry Research. 2014;219:261-7.Prospective cohort study2014-06 
Plesnicar BK et al. Therapeutic drug monitoring and pharmacogenetics--is this a way towards creative psychopharmacotherapy? Psychiatria Danubina. 2014;26:96–99.Review2014-06 
Salloum NC et al. Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Med. 2014;12:90. Review2014-05 
Lanktree MB et al. Positive perception of pharmacogenetic testing for psychotropic medications. Hum Psychopharmacol. 2014;29:287-91.Survey2014-05 
Brandl EJ et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J. 2014;14:176-81. Prospective cohort2014-04CYP2D6 and CYP2C19 variability: Increased antidepressant trials, side effects?
Drozda K et al. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy. 2014;34:166–84.Review2014-02